Amgen’s most recent trend suggests a bearish bias. One trading opportunity on Amgen is a Bear Call Spread using a strike $175.00 short call and a strike $180.00 long call offers a potential 18.76% return on risk over the next 3 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $175.00 by expiration. The full premium credit of $0.79 would be kept by the premium seller. The risk of $4.21 would be incurred if the stock rose above the $180.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Amgen is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Amgen is bearish.
The RSI indicator is at 27.65 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
Read This Before Buying Amgen Inc (AMGN) For Its Upcoming $1.15 Dividend
Sun, 12 Nov 2017 18:55:06 +0000
Shares of Amgen Inc (NASDAQ:AMGN) will begin trading ex-dividend in 3 days. To qualify for the dividend check of $1.15 per share, investors must have owned the shares prior toRead More…
Ligand (LGND) Q3 Earnings & Revenues Top, 2017 View Raised
Fri, 10 Nov 2017 15:52:03 +0000
Ligand's (LGND) earnings and revenues beat estimates. Total revenues also rise year over year on the back of higher royalty benefits. The company ups its guidance for 2017.
Short Sellers Grow More Selective on Major Biotechs
Fri, 10 Nov 2017 15:40:10 +0000
The October 31 short interest data have been compared with the previous report, and short interest in the selected biotech stocks was mixed.
Amgen Receives Positive CHMP Opinion To Expand Use Of Nplate® (romiplostim) In Pediatric Patients With Chronic Immune Thrombocytopenic Purpura
Fri, 10 Nov 2017 12:29:00 +0000
THOUSAND OAKS, Calif., Nov. 10, 2017 /PRNewswire/ — Amgen (AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to expand the current indication for Nplate® (romiplostim) to include the treatment of chronic immune (idiopathic) thrombocytopenic purpura (ITP) for patients one year of age and older who are refractory to other treatments (e.g., corticosteroids, immunoglobulins). The positive CHMP opinion was based on five studies evaluating the safety and efficacy of Nplate in children with ITP, including four completed studies (a Phase 3, a Phase 1/2 placebo-controlled study, and two long-term safety and efficacy studies) and one ongoing long-term safety and efficacy study. “Children with ITP are at risk for serious bleeding events due to low platelet counts, and currently, limited therapeutic options are available to treat this rare disease,” said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.
Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
Fri, 10 Nov 2017 12:27:00 +0000
THOUSAND OAKS, Calif., Nov. 10, 2017 /PRNewswire/ — Amgen (AMGN) and Allergan plc. (AGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the Marketing Authorization of ABP 215, a biosimilar to Avastin® (bevacizumab).
Also on Market Tamer…
Follow Us on Facebook